(Q45218109)

10 December 2017

title

Implications of HER2 amplification in small, node-negative breast cancers: do Asians differ? (English)

1 reference

10 December 2017

Fuh Yong Wong

1

1 reference

10 December 2017

Connie Siew Poh Yip

series ordinal

2

1 reference

10 December 2017

Eu Tiong Chua

series ordinal

3

1 reference

10 December 2017

publication date

1 February 2012

1 reference

10 December 2017

published in

World Journal of Surgery

1 reference

10 December 2017

volume

36

1 reference

10 December 2017

issue

2

1 reference

10 December 2017

page(s)

287-294

1 reference

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

10 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

Natural history of node-negative breast cancer: a study of 826 patients with long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

Is breast cancer the same disease in Asian and Western countries?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

The Breast Cancer Working Group presentation was divided into three sections: the epidemiology, pathology and treatment of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

True recurrence versus new primary: an analysis of ipsilateral breast tumor recurrences after breast-conserving therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

Classifying local disease recurrences after breast conservation therapy based on location and histology: new primary tumors have more favorable outcomes than true local disease recurrences

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

A review of the ethnic differences in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

Asian ethnicity and breast cancer subtypes: a study from the California Cancer Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (< or = 1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

Global trends in breast cancer incidence and mortality 1973-1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

Predictors of recurrence for patients with small (one centimeter or less) localized breast cancer (T1a,b N0 M0).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

Six-year follow-up of patients with microinvasive, T1a, and T1b breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1353-7

Benefit of taxanes as adjuvant chemotherapy for early breast cancer

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22105650

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22105650

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of fixation period on HER2/neu gene amplification detected by fluorescence in situ hybridization in invasive breast carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22105650

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00268-011-1353-7

1 reference

Dimensions Publication ID

10 December 2017

1025824924

0 references

1 reference